Author

Sarah Fischer 1

1 University of Erlangen-Nürnberg,Erlangen,Germany

EFFECTIVENESS, IMMUNOGENICITY, SAFETY AND PHARMACOECONOMIC ASPECTS FOLLOWING A SWITCH FROM REFERENCE INFLIXIMAB TO THE BIOSIMILAR SB2 IN INFLAMMATORY BOWEL DISEASE PATIENTS: A 6 MONTHS PROSPECTIVE COHORT STUDY

Sarah Fischer, Entcho Klenske, Heike Schmitt, Francesco Vitali, Simon Hirschmann, Franz Koch, Andreas Ramming, Sebastian Zundler, Sabine Krebs, Frank Dörje, Daniel Nagore, Sebastian Meyer, Wolfgang Uter, Markus F. Neurath, Raja Atreya

EFFECTIVENESS, IMMUNOGENICITY, SAFETY AND PHARMACOECONOMIC ASPECTS FOLLOWING A SWITCH FROM REFERENCE INFLIXIMAB TO THE BIOSIMILAR SB2 IN INFLAMMATORY BOWEL DISEASE PATIENTS: A 6 MONTHS PROSPECTIVE COHORT STUDY.

Sarah Fischer

EXPRESSION OF CONSTITUTIVELY ACTIVE IKK2 LEADS TO LIVER FIBROSIS AND INCREASED CARCINOGENESIS IN THE BACKGROUND OF LIVER SPECIFIC TRP53 DELETION

Michael Svinarenko, Sarah Fee Katz, Sarah Fischer, Harald Maier, Andrea Tannapfel, Thomas Seufferlein, André Lechel

RESOLUTION OF ULCERATIVE COLITIS RELATED EXTRAINTESTINAL PULMONARY MANIFESTATION BY ANTI-TNF THERAPY

Sarah Fischer

Item 1 - 4 / 4
1